News

Anti-Inflammation Treatment Masitinib Protects Against ALS Damage, Researchers Say

AB Science SA‘s anti-inflammation treatment masitinib protects muscles and nerves against damage from amyotrophic lateral sclerosis (ALS), researchers have concluded. Professor Luis Barbeito of the Institut Pasteur in Montevideo, Uruguay, presented the findings at the 27th International Symposium on ALS/MND (Motor Neuron Disease) in Dublin, Ireland, in December of 2016. Masitinib…

Evotec and Celgene Partner to Screen Novel Therapies for ALS, Other Diseases

The pharmaceutical companies Evotec and Celgene will collaborate on a drug discovery and development program to identify and develop novel disease-modifying therapies for several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The partnership will allow the screening of drug compounds developed by Celgene using Evotec’s platform of induced pluripotent…

Brains of ALS Patients ‘Wired’ Differently and That’s Evident in Disability, Study Says

Patients with amyotrophic lateral sclerosis (ALS) have a different functional brain network than healthy individuals, and that difference appears to be strongly associated with disability, according to new research. This finding supports previous research suggesting that monitoring a patient’s brain for changes in its neuronal network can aid in evaluating ALS disability and likely disease progression. The study,…

How Motor Neurons Form from Stem Cells Seen in Study That May Move ALS Cell Therapy Step Forward

The molecular steps taken to turn immature stem cells into working motor neurons were seen in new research, potentially furthering cell therapies to treat neurological disorders like amyotrophic lateral sclerosis (ALS) by teaching scientists more about this complex process. The study, “A Multi-Step Transcriptional And Chromatin State Cascade Underlies Motor Neuron Programming From Embryonic Stem Cells,” was published…

NurOwn Phase 2 Clinical Trial Results Promising, BrainStorm Cell Reports

BrainStorm Cell Therapeutics recently presented data from its Phase 2 clinical trial, showing that the company’s NurOwn stem cells technology may halt disease progression in patients with amyotrophic lateral sclerosis (ALS). The data were presented at the 27th International Symposium on ALS/MND in Dublin, Ireland. The multi-center, randomized, double blind, placebo-controlled,…